Xtant Medical (XTNT) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$109.5M

Revenue (quarter)

$23.0M

Revenue growth (year over year)

−34.96%

Gross profit (trailing twelve months)

$65.0M

Gross margin

59.39%

Net income (trailing twelve months)

−$11.1M

Net income (quarter)

−$9.4M

Net income growth (year over year)

−365.15%

Net margin

−10.17%

Return on equity

−25.16%

EPS (trailing twelve months)

−$0.08

Book value per share

$0.29

P/E (trailing twelve months)

—

Price to book

1.14

Debt to assets

49.77%

Payout ratio

—

Dividend yield

—

Company profile

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.

• Is Xtant Medical (XTNT) profitable?

  No. Xtant Medical reported a net loss of $11.1M over the trailing twelve months.

• How much revenue does Xtant Medical (XTNT) make?

  Xtant Medical generated $109.5M in revenue over the trailing twelve months, down 34.96% year over year.

• How do I buy stock in Xtant Medical (XTNT)?

  XTNT trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.